STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses ...

Greetings and welcome to the STAAR Surgical Fourth Quarter 2024 Earnings Webcast. As a reminder, this event is being recorded today Tuesday, February 11th, 2025. During today's presentation, all ...

If you’ve spent any amount of time on TikTok, you have probably seen users spamming ‘TS PMO ICL’ in comment sections. Here’s what it means. TikTok’s latest slang-heavy trend has users ...

At the Envision Summit 2025 in San Juan, Puerto Rico, Arjan Hura, MD, talked about EVO ICL surgery, its benefits, and how every ophthalmologist has the ability and training to conduct the surgery even ...

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses ...

While Chinese consumer confidence did, in fact, remain at historically low levels towards the end of last year, it appears that actual demand for STAAR's EVO lenses was even worse in FY24 than ...

STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or 'ICL', which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted ...

STAAR generates worldwide revenue almost exclusively from the sales of implantable Collamer lenses (ICLs). The company markets and sells these lenses under the "EVO" family for refractive surgery ...

The maker of implantable lenses posted revenue of $49 million in the period, also falling short of Street forecasts. Five analysts surveyed by Zacks expected $78 million. For the year, the company ...